Gene panel predicts lung cancer survival, study finds

Researchers from four leading cancer centers have confirmed that an analysis involving a panel of genes can be used to predict which lung cancer patients will have the worst survival. The finding could one day lead to a test that would help determine who needs more aggressive treatment. The study, the largest of its kind, appears online in Nature Medicine.

The researchers looked at 442 lung cancer tissue samples collected from six cancer hospitals in North America. They tested the cancer samples to look at the expression of hundreds of genes, and factored in clinical predictors such as tumor stage and the patients' gender and age. The results showed that the lung cancers could be divided into groups with better and worse survival rates.

Typically, lung cancer patients receive chemotherapy after surgery to reduce the risk of the cancer coming back. But specialists know that some patients with stage I disease, the earliest stage, have an aggressive disease with poor prognosis while some patients with more advanced stage II disease have a relatively good prognosis. The question is how to identify which patients need the additional therapy and which patients could potentially avoid it.

"We found that looking at clinical data along with gene expression can be a more reliable indicator. Gene expression is not just a black box approach – which a lot of researchers think it is. Sometimes knowing the context actually helps you use that information more efficiently," says study author David Beer, Ph.D., professor of surgery and radiation oncology at the University of Michigan Medical School and co-director of the Cancer Genetics Program at the U-M Comprehensive Cancer Center.

Lung cancer is particularly complex, with multiple types and subtypes, most of which are directly related to smoking. There are many genetic alterations induced by tobacco smoke exposure. To be able to offer one simple gene test for the disease, scientists would need to accurately model the known cellular diversity and the potential differences underlying the aggressiveness between lung cancers.

"Our findings suggest that there is a potential for successfully predicting lung cancer prognosis based on gene expression, but it is likely to be more difficult to develop a clinically useful test than has been suggested by previous studies. It's going to require more assay standardization and a large prospective study to identify a signature that is ready for clinical use," says study author Kerby Shedden, Ph.D., associate professor of statistics at U-M.

The researchers will continue to refine this process, identifying the important genes and testing them on tissue samples. They also plan in the future to test their predictors in a prospective trial, enrolling patients as they are diagnosed and following their progress. Enrollment for this trial has not begun.

Four institutions formed a consortium with support from the National Cancer Institute, to develop and validate gene expression signatures of lung cancers. The four institutions are the University of Michigan Comprehensive Cancer Center, H. Lee Moffitt Cancer Center and Research Institute in Tampa, Fla., Memorial Sloan-Kettering Cancer Center in New York, and Dana-Farber Cancer Institute in Boston.

Methodology: The researchers collected lung cancer tissue samples from six centers and grouped them into four sets based on the laboratories where the samples were processed. Two sets served as the "training set," in which researchers looked at several possible gene expression methods to determine whether they could be predictive of patient outcome. They then looked at the other two additional tumor sets for which all outcome data had remained unknown and blinded to the researchers, called "validation sets," to assess whether the outcome of the training set could be duplicated.

Source: University of Michigan

Related stories:

Scientists identify novel inhibitor of human microRNA
Scientists at The Wistar Institute and their colleagues have identified, for the first time, a molecule that can regulate microRNAs – short strands of RNA that play a vital role in gene expression and are closely associated with cancer. The discovery points the way to the development of a new generation of cancer drugs.
Gene that causes childhood cancer neuroblastoma is found
Scientists have discovered gene mutations that are the main cause of the inherited version of the childhood cancer neuroblastoma. In addition, the researchers found that the same mutations play a significant role in high-risk forms of non-inherited neuroblastoma, the more common form of the disease.
Scientists nail childhood nerve cancer gene
Researchers have identified the hereditary gene mutations behind a deadly form of childhood cancer, opening the way to genetic tests in high-risk families, according to study released Sunday.
If your first cigarette gave you a buzz and you now smoke, a gene may be to blame
Anyone who has ever tried smoking probably remembers that first cigarette vividly. For some, it brought a wave of nausea or a nasty coughing fit. For others, those first puffs also came with a rush of pleasure or "buzz."
New approach to cancer: Find most tightly controlled genes
Scientists at a Duke University medical school in Singapore have found a new way to study cancer that could be very useful for developing targeted therapies against cancer and possibly many other diseases.
15 human genomes each week
The Wellcome Trust Sanger Institute has sequenced the equivalent of 300 human genomes in just over six months. The Institute has just reached the staggering total of 1,000,000,000,000 letters of genetic code that will be read by researchers worldwide, helping them to understand the role of genes in health and disease. Scientists will be able to answer questions unthinkable even a few years ago and human medical genetics will be transformed.
Cancer cells revert to normal at specific signal threshold, researchers find
Cancer starts when key cellular signals run amok, driving uncontrolled cell growth. But scientists at the Stanford University School of Medicine report that lowering levels of one cancer signal under a specific threshold reverses this process in mice, returning tumor cells to their normal, healthy state. The finding could help target cancer chemotherapy to tumors while minimizing side effects for the body's healthy cells.
Faulty DNA repair could be a risk factor for lung cancer in nonsmokers
People who have never smoked but whose cells cannot efficiently repair environmental insults to DNA are at higher risk of developing lung cancer than those with effective genomic repair capability, according to researchers from the Department of Epidemiology at The University of Texas M. D. Anderson Cancer Center.

News discussion:

Medicine & Health news